Greater LDL-C Reduction With Bempedoic Acid in Setting of Metabolic Syndrome
The efficacy of bempedoic acid was analyzed based on glycemic parameters and baseline metabolic syndrome status.
The efficacy of bempedoic acid was analyzed based on glycemic parameters and baseline metabolic syndrome status.
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH.
Factors to consider include evaluation of secondary causes, optimization of diet and lifestyle interventions, implementation of statin therapy.
The researchers wanted to determine the value of LDL-C as a risk biomarker for coronary heart disease, atherosclerotic cardiovascular disease, and stroke events and deaths for people stratified by age.
For patients hospitalized with COVID-19, prior use of statins, with or without antihypertensives, is associated with a reduced risk for death.
Researchers investigate whether asymptomatic atherosclerotic CVD can be prevented with an aggressive medical treatment that reduces LDL cholesterol to <60 mg/dl.
This study aimed to assess the effects of the various elements of metabolic syndrome on carotid plaque destabilization.